These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21658633)

  • 21. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
    Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
    Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease.
    Pukhalsky AL; Shmarina GV; Kapranov NI; Kokarovtseva SN; Pukhalskaya D; Kashirskaja NJ
    Mediators Inflamm; 2004 Apr; 13(2):111-7. PubMed ID: 15203552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapies for cystic fibrosis.
    Simakajornboon N; Davis SH
    J La State Med Soc; 1998 Dec; 150(12):629-37. PubMed ID: 9926704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging therapies in cystic fibrosis.
    Anderson P
    Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
    Aaron SD
    Paediatr Respir Rev; 2007 Sep; 8(3):256-61. PubMed ID: 17868924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative proteomics (2-D DIGE) reveals molecular strategies employed by Burkholderia cenocepacia to adapt to the airways of cystic fibrosis patients under antimicrobial therapy.
    Madeira A; Santos PM; Coutinho CP; Pinto-de-Oliveira A; Sá-Correia I
    Proteomics; 2011 Apr; 11(7):1313-28. PubMed ID: 21337515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological therapy for cystic fibrosis: from bench to bedside.
    Becq F; Mall MA; Sheppard DN; Conese M; Zegarra-Moran O
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S129-45. PubMed ID: 21658632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials.
    Bilton D; Canny G; Conway S; Dumcius S; Hjelte L; Proesmans M; Tümmler B; Vavrova V; De Boeck K
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S79-81. PubMed ID: 21658647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.
    Sherrard LJ; Tunney MM; Elborn JS
    Lancet; 2014 Aug; 384(9944):703-13. PubMed ID: 25152272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic management of cystic fibrosis.
    Kuhn RJ; Nahata MC
    Clin Pharm; 1985; 4(5):555-65. PubMed ID: 3931959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exhaled nitric oxide increases following admission for intravenous antibiotics in children with cystic fibrosis.
    Jaffé A; Slade G; Rae J; Laverty A
    J Cyst Fibros; 2003 Sep; 2(3):143-7. PubMed ID: 15463863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease.
    Döring G; Parameswaran IG; Murphy TF
    FEMS Microbiol Rev; 2011 Jan; 35(1):124-46. PubMed ID: 20584083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aerosol antibiotics: considerations in pharmacological and clinical evaluation.
    Dudley MN; Loutit J; Griffith DC
    Curr Opin Biotechnol; 2008 Dec; 19(6):637-43. PubMed ID: 19036576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory infections: established therapy and its limitations.
    Grassi GG
    Clin Ther; 1985; 7 Suppl A():19-36. PubMed ID: 3907844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
    Caverly LJ; Zhao J; LiPuma JJ
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.